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Implications of C1q/TNF-related 
protein superfamily in patients with 
coronary artery disease
Yanwei Zhang1,3,4, Caihong Liu1,4, Jing Liu1, Rui Guo1, Zheyi Yan1,3, Wenxia Liu1, 
Wayne Bond Lau2, Xiangying Jiao1, Jimin cao1, Kun Xu3, Yongping Jia3, Xinliang Ma2 & 
Yajing Wang2*
The C1q complement/TNF-related protein superfamily (CTRPs) displays differential effects on the 
regulation of metabolic homeostasis, governing cardiovascular function. However, whether and how 
they may serve as predictor/pro-diagnosis factors for assessing the risks of coronary artery disease 
(CAD) remains controversial. Therefore, we performed a clinical study to elaborate on the implication 
of CTRPs (CTRP1, CTRP5, CTRP7, and CTRP15) in CAD. CTRP1 were significantly increased, whereas 
CTRP7 and CTRP15 levels were decreased in CAD patients compared to the non-CAD group. Significant 
differences in CTRP1 levels were discovered between the single- and triple-vascular-vessel lesion 
groups. ROC analysis revealed that CTRP7 and CTRP15 may serve as CAD markers, while CTRP1 may 
serve as a marker for the single-vessel lesion of CAD. CTRP1 and CTRP5 can serve as markers for the 
triple-vessel lesion. CTRP1 may serve as an independent risk predictor for triple-vessel lesion, whereas 
CTRP15 alteration may serve for a single-vessel lesion of CAD. CTRP1 may serve as a novel superior 
biomarker for diagnosis of severity of vessel-lesion of CAD patients. CTRP7, CTRP15 may serve as more 
suitable biomarker for the diagnosis of CAD patients, whereas CTRP5 may serve as an independent 
predictor for CAD. These findings suggest CTRPs may be the superior predictive factors for the vascular 
lesion of CAD and represent novel therapeutic targets against CAD.
Coronary artery disease (CAD) is one of the major cardiovascular diseases, which has a serious impact on human 
health1. CAD is a group of diseases including myocardial infarction, sudden angina pectoris, unstable angina 
pectoris, myocardial infarction, and sudden coronary death2. Multiple risk factors for CAD have been identified, 
which are highly associated with metabolism influencer/regulators including obesity, hypertension, dyslipidemia, 
diabetes, smoking, gender, age, etc.3. However, the sensitivity of the indicators limits the prediction and prognosis 
of CAD. Identification of new marker or indicator is in great need.
Previous studies suggest that adipokines, well-defined adipocyte endocrine factors, are important deter-
minants for cardiovascular disorders with or without diabetes. Previous investigations implicate adiponectin 
(APN)’s circulationary level is negatively associated with patients who suffered coronary artery disease and4. 
CTRP (C1q complement/TNF-related protein) as a newly discovered family have shown diversity and wide dis-
tribution. Some of CTRP family members have similar metabolic effects with that of adiponectin, whereas others 
exert opposite effect as that adiponectin. Although emerging evidence suggests that CTRPs may serve as indi-
cators for metabolic disorders, whether and how CTRPs may display its own unique potential relationship in 
predicting disease, especially cardiovascular disorders, is largely under-investigated.
CTRP family contains 15 family members (CTRP1 to CTRP15). Their functions display the differences 
and are highly related to their distributions5. Of all CTRPs identified to date, CTRP1, CTRP3, CTRP5, CTRP9, 
CTRP12, CTRP7, and CTRP13 have been reported to exhibit metabolic regulation and cardiovascular effects in 
animal models6–8. CTRP7 circulating levels are reduced in diet-induced diabetic or obese5,9, and CTRP7 deletion 
attenuates obesity-linked glucose intolerance, adipose tissue inflammation, and hepatic stress10. CTRP15 is a 
newly discovered actin that binds skeletal muscle and lipids in response to changes in energy status and pre-
dicts changes in metabolic circuits11. However, few CTRP members have been investigated in human studies and 
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results are often controversial. For instance, one study reported that CTRP1 may slow the pathogenesis of early 
atherosclerosis and prevent the development of pathological blood vessels12. However, another study demon-
strated that CTRP1 level is associated with coronary artery disease13,14. CTRP5 level is related to drug-eluting 
stent implantation after stent restenosis15,16. However, the pathogenic or diagnostic role of CTRP5 in coronary 
diseases remain unclear in CAD patients.
Although above results suggest that CTRPs are associated with metabolism syndromes and play important 
role in the regulating cellular metabolism,, unclear relationship between circulating CTRPs and coronary artery 
disease in clinic patients, complexity of CTRP family, and unclear interrelationship between members of CTRP 
family with different biological function, limited the CTRPs’s clinical application both in therapeutic strategy 
exploration and as prognostic biomarkers. Therefore, we initiated a clinic investigation on plasma concentrations 
of CTRP1, CTRP5, CTRP7, and CTRP15, aiming to identify high potential markers to guidance new therapeutic 
strategy specifically in coronary artery disease, and to predict the severity of CAD. Additionally, the interrelation-
ship of CTRP family in CAD will be assessed.
Results
Subjects characteristics. A total of 190 subjects were enrolled in this study. All the demographic data, base-
line clinical and biochemical characteristics of the study subjects were summarized in Tables 1 and 2. Statistical 
analysis showed that CAD patients had markedly higher levels of vascular occlusion, hypertension, diabetes, 
total cholesterol (TCH), Triglyceride (TG), high density lipoprotein (HDL)-cholesterol, low density lipoprotein 
(LDL)-cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Interestingly, circulat-
ing CTRP1 was significantly high in CAD patients, while CTRP7 and CTRP15 were decreased compared to non-
CAD participants (Table 2, p < 0.01). In addition, CTRP7and CTRP15 levels were reduced in elder non-CAD 
when compared with young non-CAD controls (Table 2).
To reveal the relationship between CTRPs and vascular lesions and the severity of lesion stages, we evalu-
ated CTRPs levels in different vessel-lesions. Along with increased vascular lesions, CTRP1 and CTRP7 levels 
increased with the numbers of vessel-lesions in CAD patients (P < 0.05). CTRP5 showed increase tendency in 
age-matched groups. Notably, CTRP15 levels were decreased in CAD patients, and CTRP15 levels were lower in 
multiple vessel-lesion group than that in the single-vessel-lesion group. Furthermore, we constructed two models 
for multivariate regression analysis to assess the independent determinants for severity of diseased coronary ves-
sels. In model 1, we included all risk factors and compared multiple vessel lesions (combining double-vessel and 
triple-vessel lesion together) to single-vessel lesion. In model 2, we additionally adjusted the analysis by grouping 
single-vessel and double-vessel as primary lesion and compared with triple-vessel lesion. Both models support 
Variable
Non-CAD CAD
PYong Elder Single-vessel-Lesion Double-vessel-Lesion Triple-vessel-Lesion
Sex (M/F) 5/35 17/13 29/11 34/6 28/12 <0.001
Age (year) 34.80 ± 9.73 54.90 ± 8.29 61.13 ± 9.06 63.63 ± 10.61 64.05 ± 8.74 <0.001
Occlusion (N/Y) 40/0 30/0 36/4 36/4 30/10 <0.001
Hypertension (N/Y) 40/0 30/0 24/16 25/15 19/21 <0.001
Diabetes (N/Y) 40/0 30/0 31/9 32/8 28/12 <0.001
Smoker (N/Y) 40/0 27/3 33/7 36/4 34/6 0.106
TCH (mmol/L) 4.49 ± 0.92 4.67 ± 1.15 4.00 ± 1.06 4.07 ± 1.20 4.23 ± 1.21 0.030
Triglyceride (mmol/L) 1.03 ± 0.58 1.66 ± 0.62 1.65 ± 1.12 1.70 ± 0.82 2.17 ± 2.08 <0.001
HDL-cholesterol (mmol/L) 1.43 ± 0.36 1.02 ± 0.15 0.98 ± 0.24 0.92 ± 0.18 1.11 ± 0.76 <0.001
LDL-cholesterol (mmol/L) 2.20 ± 0.62 2.87 ± 0.88 2.29 ± 0.84 2.37 ± 0.96 3.02 ± 2.50 0.009
ALT(U/L) 20.80 ± 23.68 24.10 ± 15.00 28.96 ± 16.11 35.50 ± 37.08 40.98 ± 61.58 <0.001
AST(U/L) 27.87 ± 33.10 21.77 ± 6.48 27.61 ± 13.88 33.58 ± 28.96 38.93 ± 51.47 0.025
EF(%) 63.34 ± 8.72 62.27 ± 9.71 60.58 ± 8.91 60.03 ± 7.45 59.28 ± 9.11 0.197
Table 1. Clinical characteristics of participants in CAD and non-CAD groups. **p < 0.01 Comparison with 
non-CAD control subjects. a, p < 0.05 Comparison between single-vessel and triple-vessel.
Variable
Non-CAD CAD
PYong Elder Single-vessel-Lesion Double-vessel-Lesion Triple-vessel-Lesion
CTRP1 (ng/ml) 5.28 ± 3.52 6.69 ± 5.36 6.32 ± 6.22 8.25 ± 9.26 11.31 ± 9.99a** 0.019
CTRP5 (ng/ml) 8.95 ± 3.18 9.82 ± 4.23 14.69 ± 14.36 10.75 ± 4.71 10.26 ± 10.00 0.080
CTRP7 (ng/ml) 44.81 ± 41.02 20.83 ± 23.72** 29.70 ± 51.53** 34.83 ± 53.62** 38.21 ± 78.17** 0.005
CTRP15 (ng/ml) 50.21 ± 34.79 40.40 ± 42.08* 40.40 ± 38.18* 26.82 ± 31.85*** 27.29 ± 29.48*** <0.001
Table 2. Circulating levels of CTRPs of participants in CAD and non-CAD groups. **p < 0.01 Comparison 
with non-CAD control subjects. a, p < 0.05 Comparison between single-vessel and triple-vessel.
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that CTRP1 is associated with the severity of vessel-lesion of CAD (Tables 3 and 4). CTRP5 may serve as an inde-
pendent predictor for CAD.
To further clarify the relationship between CTRPs and CAD, we performed a serial analysis. First, as illus-
trated in Table 5, we build a multivariate model among the significant variables noted by univariate analysis to 
determine potential screening markers for CAD. Results showed that CAD is highly correlated with Sex, age, 
diabetes and AST (p < 0.05). CTRP5 was an independent predictor for CAD (Table 5). Meanwhile, Sex, age, dia-
betes, smoking, TCH, TG, HDL-C, ALT, CTRP1 and CTRP15 were significantly positively associated with CAD 
(Table 6). Logistic regression analysis as shown in Table 7 and 8 indicated that reduced CTRP15 was a high-risk 
factor for a single-vessel lesion in CAD whereas increased CTRP1, occlusion and smoking were the high-risk 
factors for triple-vessel lesions of CAD.
To assess whether CTRPs can serve as a marker for CAD, a receiver operating characteristic (ROC) curve 
was constructed to evaluate the diagnostic value of CTRPs for CAD. As illustrated in Fig. 1, the AUC (area under 
the curve) was 0.626 for CTRP7 (P < 0.01, Fig. 1A, n = 120) and 0.665 for CTRP15 (p < 0.001, Fig. 1B, n = 120), 
confirming specificity and sensitivity of CTRP7 and CTRP15 as biomarkers for CAD. The ROC analysis results of 
CTRP5 and CTRP1 showed the AUC was 0.529 and 0.554 respectively, failed to serve as biomarkers for CAD as a 
whole. Notably, the AUC of CTRP1 was 0.613 (95% confidence interval 0.509–0.718, P = 0.044) for single-vessel 
lesions (Fig. 2A), and AUC was 0.650 (p = 0.007) for triple-vessel (Fig. 2B). Furthermore, the AUC of CTRP1 for 
multiple-vessel lesions was 0.613 (p = 0.044) (Fig. 2C), hence, CTRP1 value was the optimistic selected mod-
els for prognosticating vessel-lesions in CAD. Although the AUC of CTRP5 for triple-vessel lesions was 0.642 
(p = 0.011), the signal-vessel lesion and multiple-vessel lesion failed to serve as a marker (Fig. 3). Taken together, 
these results suggest that CTRP7 and CTRP15 may serve as biomarkers for CAD as whole while CTRP1 may 
serve as a marker for severity of vessel-lesions.
To identify the etiology of altered CTRPs in CAD patients, we examined whether CTRPs is associated with 
other risk factors. Multiple linear regression was used to determine the relationship of CTRPs with other risk 
factors. As shown in Tables 9 and 10, the results revealed that CTRP5 and CTRP7 were not associated with 
any other variables. However, serum CTRP1 was positively associated with age and vascular occlusion. When 
Variable OR OR CI95% P
CTRP1(ng/ml) 1.049* 1.002–1.097 0.039
Sex(M/F) 1.289 0.461–3.599 0.628
Age(year) 0.998 0.952–1.046 0.934
Hypertension(N/Y) 1.884 0.816–4.347 0.138
HDL-C(mmol/L) 2.060 0.716–5.930 0.180
TCH(mmol/L) 1.152 0.813–1.632 0.426
Smoker(N/Y) 0.755 0.217–2.621 0.658
Table 3. Correlation between CTRP1 and number of diseased coronary vessels (multivariate regression 
analysis). Comparison single-vessel with double-vessel and triple-vessel lesion.
Variable OR OR CI95% P
CTRP1(ng/ml) 1.066* 1.004–1.132 0.037
Sex(M/F) 0.384 0.132–1.119 0.079
Age(year) 1.041 0.992–1.092 0.106
Hypertension(N/Y) 1.016 0.441–2.343 0.970
HDL-C(mmol/L) 1.180 0.477–2.919 0.720
TCH(mmol/L) 1.151 0.802–1.650 0.446
Smoker(N/Y) 0.362 0.107–1.226 0.102
Table 4. Correlation between CTRP1 and number of diseased coronary vessels (multivariate regression 
analysis). Comparison single-vessel and double-vessel with triple-vessel lesion.
Variable OR OR CI95% P
Sex 8.92** 1.91–41.76 0.005
Age 0.82*** 0.74–0.89 <0.001
Diabetes 207.82** 5.53–7811.55 0.004
CTRP5 1.17* 0.73–0.99 0.038
AST 0.96* 0.93–0.99 0.029
Table 5. Correlation between CAD and CTRPs (multivariate regression analysis). *p < 0.05. **p < 0.01. 
**p < 0.001.
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other variables remain the same, CTRP1 increases by 0.088 ng/ml for each additional year of age (Table 9). 
Meanwhile, there was no evidence revealing the positive interrelationship among the CTRP family members in 
CAD population.
In contrast, age, diabetes, and TCH had a significant association with CTRP15. Serum CTRP15 was inversely 
correlated with age and diabetes, but TG was positively correlated with CTRP15. In order to further determine 
the relationship between CTRPs and severity of vessel-lesions in coronary artery disease, we have studied the 
correlation between the number of lesions in CAD and clinical indicators. The results showed that CTRP1 level is 
positively correlated with AST in single-vessel disease (Table 11). CTRP15 and diabetes were negatively correlated 
with the three-vessel disease (Table 12).
Discussion
We reported a discovery of new biomarkers for coronary artery disease. The current study demonstrated that 
CTRP7 and CTRP15 may serve novel biomarkers of CAD, and CTRP1 may predict the vessel-lesion severity in 
CAD. Moreover, CTRP5 may serve an independent predictor for CAD. In addition, compared with the control 
group, concentrations of both CTRP5 and CTRP7 were significantly decreased in CAD patients while CTRP1 
concentrations were elevated.
In recent years, there have been many studies investigating serum levels of CTRP1 and coronary artery dis-
ease. Studies have shown that CTRP1 is a marker of human atherosclerosis and promotes atherosclerosis in 
Variable
Univariate Analysis
OR ORCI95% P
Sex(M/F) 6.846*** 3.56–13.18 <0.001
Age(year) 1.15** 1.11–1.20 0.001
Diabetes(N/Y) 21.99** 2.92–165.41 0.003
Smoker(N/Y) 3.69* 1.04–13.07 0.043
TCH(mmol/L) 0.69** 0.53–0.90 0.007
TG(mmol/L) 1.97** 1.27–3.06 0.002
HDL-C(mmol/L) 0.17** 0.06–0.47 0.001
LDL-C(mmol/L) 1.04 0.83–1.31 0.710
ALT(U/L) 1.03* 1.01–1.05 0.011
AST(U/L) 1.02 0.10–1.03 0.114
EF(%) 0.97 0.92–1.02 0.198
CTRP1(ng/ml) 1.06* 1.01–1.12 0.022
CTRP5(ng/ml) 1.05 0.10–1.11 0.058
CTRP7(ng/ml) 1.00 0.99–1.01 0.967
CTRP15(ng/ml) 0.99** 0.98–0.10 0.009
Table 6. Logistic regression analysis of related risk factors. for CAD. **p < 0.01.*p < 0.05. **p < 0.001.
Variable
Univariate Analysis
OR ORCI95% P
Sex(M/F) 1.307 0.547–3.119 0.547
Age(year) 0.970 0.931–1.010 0.143
Occlusion(N/Y) 0.524 0.160–1.710 0.284
Hypertension(N/Y) 0.815 0.377–1.761 0.603
Diabetes(N/Y) 0.871 0.355–2.138 0.763
Smoker(N/Y) 1.485 0.519–4.247 0.461
TC(mmol/L) 0.890 0.636–1.246 0.498
TG(mmol/L) 0.834 0.586–1.186 0.312
HDL-C(mmol/L) 0.822 0.331–2.044 0.674
LDL-C(mmol/L) 0.792 0.548–1.146 0.216
ALT(U/L) 0.992 0.976–1.007 0.287
AST(U/L) 0.987 0.967–1.008 0.219
EF(%) 1.013 0.968–1.061 0.572
CTRP1(ng/ml) 0.945 0.892–1.000 0.051
CTRP5(ng/ml) 1.039 0.997–1.083 0.067
CTRP7(ng/ml) 0.998 0.991–1.005 0.571
CTRP15(ng/ml) 1.011* 1.000–1.023 0.045
Table 7. Logistic regression analysis of related risk factors for single-vessel of CAD. *p < 0.05.
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mice17–19. The serum of the three-vessel disease had a high concentration of CTRP1 than the single-vessel disease, 
which was consistent with our findings. Our results indicated that compared with non-CAD people, the serum 
level of CTRP1 was elevated and correlated with CAD. CTRP1 highly correlated with the stages of vessel-lesion. 
Although CTRP1 was a significant factor for predicting vessel-lesion stages in CAD, it failed to be a diagnostic 
biomarker to CAD. This is inconsistence with previous report by other group13. Small patients’ populations and 
limited race (Chinese Han population) could be the reason to cause this discrepancy. However, it acts as a bio-
marker for the increase of the vessel-lesion level. The increased level of CTRP1 in circulation may be attributed 
to disturbed flow and other risk factors-induced inflammatory cytokines20,21. To further explore the risk factor 
for elevated CTRP1 and elaborate the relationship between clinical indicators and CTRP1, we applied multiple 
linear regression assay. The results indicated that plasma CTRP1 levels were positively correlated with age and 
vascular occlusion. Furthermore, CTRP1 was positively correlated with AST in single-vessel disease. Despite the 
advantageous findings of our study regarding the role of CTRP1 in CAD related vessel lesion, we recognize some 
limitations. We did not investigate other vascular disease relationship with CTRP1 and other possible pathogenic 
molecules including other CTRP family members. It is highly desirable to conduct additional studies regarding 
CTRP1 role in pathogenesis of CAD with larger samples of patients utilizing prospective designs.
CTRP5 is wildly expressed in various cells, with the highest expression level in adipose tissue22. It inhibits 
adiponectin and resistin release in a dose-dependent manner16. Simultaneously, CTRP5 can promote transcytosis 
and oxidative modification of low-density lipoprotein and accelerate atherosclerosis development23. Studies have 
shown that CTRP5 can be used as a biomarker for potential new inflammatory chronic obstructive pulmonary 
disease and in patients with coronary in-stent restenosis since serum CTRP5 levels are significantly elevated24. 
However, there are few studies investigated the relationship between CTRP5 and coronary artery disease. In our 
study, we divided the recruited patient’s population into two groups (elder and young) in the normal physical 
examination group. Three stages of vessel-lesion in diagnosed as coronary artery disease group and the CTRP5 
levels were compared among the groups. The results showed no differences within the non-CAD group in dif-
ferent age. However, CTRP5level was increased in CAD group when compared with non-CAD. Notably, the 
concentration of serum CTRP5 shown an increasing tendency in a single-vessel lesion group than the three-vessel 
lesion group. The small sample size and the controversial deleterious effect of CTRP5 in the vascular system may 
contribute to the unparalleled phenomenon between CTRP5 and the level of vessel lesions16,23,25.
Although circulating CTRP7 level has been reported to be elevated in obese people, and CTRP7 knockout 
mice exhibit elevated glucose metabolism, decreased adipose tissue inflammation, liver fibrosis, cellular oxida-
tion, and endoplasmic reticulum stress in10, the CTRP7 circulating levels and coronary artery disease is largely 
unknown. Studies have shown that circulating CTRP15 concentration and its gene expression are affected by 
metabolism26. CTRP15 may potentially be used as a circulating biomarker for predicting cardiovascular dis-
ease (CVD) risk in obese and T2DM patients27. In our study, serum CTPR7 and CTRP15 levels in CAD were 
reduced compared with the non-CAD group. CTRP7 and CTRP15 are novel identified diagnostic biomarker for 
CAD, while CTRP1 and CTRP5 fail in this study. These results suggest that CTRP7 and CTRP15 presents more 
sensitivity and stability as biomarkers than the other two. Meanwhile, the result showed that CTRP15 was nega-
tively correlated with age and diabetes in coronary artery disease patients; and it is positively correlated with TG 
levels. Further analysis revealed that the negative correlation between CTRP15 and diabetes is significant in the 
three-vessel lesion of CAD.
We further carried out multiple regression analysis and found that CTRP5 can be an independent indicator 
for CAD, but it failed to predict the severity of vessel-lesion, and CTRP5 might be a possible therapeutic target in 
Variable
Univariate Analysis
OR ORCI95% P
Sex(M/F) 1.588 0.670–3.763 0.293
Age(year) 1.019 0.978–1.061 0.363
Occlusion(N/Y) 3.000* 1.079–8.341 0.035
Hypertension(N/Y) 1.747 0.812–3.760 0.154
Diabetes(N/Y) 1.588 0.670–3.763 0.293
Smoker(N/Y) 3.69* 1.04–13.07 0.043
TC(mmol/L) 1.162 0.837–1.613 0.370
TG(mmol/L) 1.278 0.945–1.727 0.112
HDL-C(mmol/L) 2.170 0.768–6.131 0.144
LDL-C(mmol/L) 1.346 0.974–1.859 0.071
ALT(U/L) 1.005 0.996–1.014 0.391
AST(U/L) 1.007 0.995–1.018 0.263
EF(%) 0.986 0.92–1.02 0.531
CTRP1(ng/ml) 1.052* 1.006–1.099 0.025
CTRP5(ng/ml) 0.971 0.925–1.020 0.243
CTRP7(ng/ml) 1.002 0.996–1.007 0.621
CTRP15(ng/ml) 0.994 0.982–1.006 0.334
Table 8. Logistic regression analysis of related risk factors for triple-vessel of CAD. *p < 0.05.
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prevention or ameliorating CAD in future study. In addition, consistent with other studies28, gender, age, diabetes, 
and AST are all risk factors for CAD.
Our research has some limitations. The first is relatively small sample size and is Chinese Han population 
only. Secondly, our survey was a case-controlled study by which it cannot determine the incident rate of disease 
in exposed and non-exposed groups. Thirdly, we utilized AUC >0.6 as cutoff for the resultant logistic-regression 
based ROC analyses. However, CTRPs are not pre-existing risk model in CAD and our study was restricted to a 
small study size. This factors AUC has value for evaluating CAD risks even with a cutoff value of 0.6. Fourthly, 
mechanisms causing circulating CTRPs level alteration need to be further explored. Our preliminary experi-
ments suggest that unbalanced miRNA pool produced by dysfunctional adipocytes may initiate pathological 
long-distance communication between adipocytes and cardiomyocytes, causing CTRPs level alteration, abnormal 
CTRP9 assembling and expression. Finally yet importantly, we needed additional in vivo animal studies to eluci-
date the physiology and mechanism of action of CTRP in the development of CAD.
In conclusion, we have demonstrated that circulating CTRP1 can predict the severity of vessel-lesions in coro-
nary artery disease, and CTRP7 and CTRP15 can serve as new CAD diagnostic biomarker. In addition, our study 
showed that CTRP15 is inversely associated with diabetes in three-vessel coronary artery disease. CTRP5 is the 
independent risk for CAD. The new discovered CTRPs provide the future therapeutic target and pre-diagnostic 
biomarker for coronary artery disease.
Variable AUC SE P-value 95%CI
CTRP7 (ng/ml) 0.626 0.041 0.004 0.546-0.706
ROC curves, for CAD diagnosis, by circulang 
CTRP7 level.
Variable AUC SE P-value 95%CI
CTRP15 (ng/ml) 0.665 0.040 <0.001 0.587-0.743
ROC curves, for CAD diagnosis, by 
circulang CTRP15 level.
A B
Variable AUC SE P-value 95%CI
CTRP1 (ng/ml) 0.554 0.041 0.211 0.473-0.635
ROC curves, for CAD diagnosis, by 
circulang CTRP1 level.
D
Variable AUC SE P-value 95%CI
CTRP5(ng/ml) 0.529 0.042 0.512 0.447-0.610
ROC curves, for CAD diagnosis, by 
circulang CTRP5 level.
C
Figure 1. ROC curves for CAD diagnosis by CTRPs level. (A) ROC curves for CAD diagnosis by CTRP7 level. 
(B) ROC curve for CAD diagnosis by circulating CTRP15 level. (C) ROC curve for CAD diagnosis by CTRP5 
level. (D) ROC curve for CAD diagnosis by CTRP1 level.
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Methods
Participants and eligibility. The patients were enrolled in the first affiliated Hospital of Shanxi Medical 
University from January 2017 to September 2018. A total of 190 subjects attended. The research included 40 
healthy control subjects, 30 patients without stenosis after coronary angiography, and 120 patients with coronary 
artery disease (40 patients with a single vessel, 40 patients with double-vessel and 40 patients with triple-vessel). 
All research protocols were approved by the Ethics Committee of Shanxi Medical University and performed in 
accordance with the latest version of the Declaration of Helsinki. Moreover, all patients and control subjects 
were given written informed consent. The diagnostic criteria of CAD were a 50% or greater organic stenosis of 
at least one main coronary artery as confirmed by coronary angiogram, two stenosis ≥50% was considered as a 
double-vessel disease, and more than two stenoses was defined as a triple-vessel disease. Exclusion criteria for this 
study were: old myocardial infarction, congestive heart failure, severe hepatic and renal dysfunction, malignancy, 
a history of trauma or surgery within one-month, valvular heart disease, pregnancy, or any factor affecting body 
weight such as hyperthyroidism, corticosteroids, or contraceptives, or acute and chronic infection.
Biochemical and hormonal analysis. The arterial blood extracted directly from the sheath of radial artery 
before coronary angiography was separated into the Eppendorf tube at 4 °C for 20 minutes by 3000 rpm centrifu-
gation, then frozen and stored at −80 °C until determined. Total cholesterol(TC), triglycerides(TG), high-density 
Variable AUC SE P-value 95%CI
CTRP1(ng/ml) 0.613 0.053 0.044 0.509-0.718
ROC curves, for single-vessel-lesion  
of CAD diagnosis
Variable AUC SE P-value 95%CI
CTRP1(ng/ml) 0.650 0.052 0.007 0.548-0.752
ROC curves, for triple-vessel-lesion  
of CAD diagnosis
ROC curves, for mulple-vessel-lesion  of 
CAD diagnosis, by circulang CTRP1 level.
Variable AUC SE P-value 95%CI
CTRP1?ng/ml) 0.613 0.053 0.044 0.509-0.717
A B
C
Figure 2. ROC curves for vessel-lesion of CAD diagnosis by CTRP1 level. (A) ROC curve for single-vessel-
lesion of CAD diagnosis by CTRP1 level. (B) ROC curve for triple-vessel-lesion of CAD diagnosis by CTRP1 
level. (C) ROC curve for multiple-vessel-lesion of CAD diagnosis by CTRP1 level.
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ROC curves, for triple-vessel  of CAD diagnosis, by circulang CTRP5 level.
Variable AUC SE P-value 95%CI
CTRP5 (ng/ml) 0.642 0.058 0.011 0.528-0.756
ROC curves, for mulple-vessel  of CAD diagnosis, by circulang CTRP5 level.
Variable AUC SE P-value 95%CI
CTRP5(ng/ml) 0.591 0.054 0.106 0.485-0.697
A
B
Figure 3. ROC curves for vessel-lesion of CAD diagnosis by CTRP5 level. (A) ROC curve for triple-vessel-
lesion of CAD diagnosis by CTRP5 level. (B) ROC curve for multiple-vessel-lesion of CAD diagnosis by CTRP5 
level.
Variable β SE P
Sex(M/F) 0.984 1.248 0.431
Age(year) 0.088* 0.042 0.037
Occlusion(N/Y) 4.445* 1.889 0.020
Diabetes(N/Y) 0.733 1.698 0.666
TCH(mmol/L) −0.531 0.546 0.332
HDL-C(mmol/L) 1.253 1.326 0.346
Smoker(N/Y 2.791 1.903 0.144
AST(U/L) 0.022 0.017 0.202
TG(mmol/L) 0.906 0.506 0.075
Hypertension(N/Y) 0.033 1.526 0.983
Table 9. Multiple linear regression analysis of CTRP1 and clinical indicators. *p < 0.05.
Variable β SE P
Sex(M/F) 4.222 5.832 0.470
Age(year) −0.606** 0.196 0.002
Occlusion(N/Y) 2.675 8.828 0.762
Diabetes(N/Y) −19.379* 7.935 0.016
TCH(mmol/L) 6.162* 2.553 0.017
HDL-C(mmol/L) −5.271 6.197 0.396
Smoker(N/Y) 4.577 8.893 0.607
AST(U/L) −0.132 0.081 0.104
TG(mmol/L) −0.990 2.365 0.676
Hypertension(N/Y) 11.924 7.134 0.096
Table 10. Multiple linear regression analysis of CTRP15 and clinical indicators. *p < 0.05.
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lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, homocysteine (HCY) were determined 
by commercial kit via Hitachi 7600 biochemical automatic analyzer (Hitachi, Tokyo, Japan).
Echocardiographic examination. The echocardiographic measurements were carried out while the 
patients were in the left lateral decubitus with standard precordial positions by Philips Epiq 7C Cardiology 
Ultrasound machine (Los Angeles, CA, USA). The left ventricle ejection fraction (LV EF) was assessed with 
biplane method of disks (modified Simpson’s rule) according to the American Society of Echocardiography 
(ASE). LVEF = [(LV end-diastolic volume)- (LV end-systolic volume)]/ (LV end-diastolic volume).
Measurement of plasma CTRP1, CTRP5, CTRP7 and CTRP15. Plasma CTRP1, CTRP5, CTRP7, and 
CTRP15 levels were measured by commercial enzyme-linked immunosorbent assay (ELISA) kit (Cat, SK00083-
01 for CTRP1; Cat, SK00594-06 for CTRP5; Cat, SK00396-09 for CTRP7; SK00393-19 for CTRP15, Aviscera 
Bioscience, Santa Clara, CA) per manufacturer’s instructions. Intra- and inter-assay coefficients of variation (CV) 
for CTRP1, CTRP5, and CTRP15 were 6–8% and 8–12% respectively, and intra- and inter-assay coefficients of 
variation for CTRP7 were 4–6% and 8–10%, respectively.
Statistical analysis. Descriptive analysis was applied, and quantitative data were conducted by the 
Shapiro-Wilk test for normality. Continuous variables are expressed as mean ± standard error (SE). Data (Sex, 
Smoker, Diabetes) that did not conform to normality distribution were expressed as median ± interquartile (IQR). 
We first examined differences between groups of the phenotypes of interest in the control, single-vessel-lesion, 
double-vessel-lesion, and triple-vessel-lesion by the Mann-Whitney U test to compare of continuous variables 
and the Chi-square test for statistical inference of categorical variables. To assess the effect of the subjects with 
different lesions, we applied a Chi-square test on different groups.
Next, we used logistic regression to estimate the association between CAD and case-control status of all other 
parameters as defined above. In addition to the use of multivariate regression for determining potential screening 
markers for CAD, we adjusted our model for other risk factors by univariate regression analysis and evaluated the 
collinearity diagnostics. The predicted probability of being diagnosed with CAD was used as a surrogate marker 
to construct receiver operating characteristic (ROC curves). The area under the ROC curve (AUC) served as an 
accuracy index evaluating the diagnostic performance of the noted marker. We used multiple linear regression to 
describe the dependencies between CTRPs and multiple independent variables in CAD.
All statistical analyses were performed using SPSS 20.0 (Chicago, IL, USA). P-value less than 0.05 in a 
two-tailed test were considered statistically significant.
Received: 5 August 2019; Accepted: 26 December 2019;
Published: xx xx xxxx
Variable β SE P
Sex(M/F) −0.705 2.685 0.795
Age(year) 0.119 0.138 0.395
Occlusion(N/Y) 0.406 3.626 0.912
Diabetes(N/Y) 2.589 2.413 0.292
TCH(mmol/L) −0.049 1.276 0.969
HDL-C(mmol/L) 1.745 5.786 0.765
Smoker(N/Y 4.298 2.935 0.154
AST(U/L) 0.168* 0.079 0.044
TG(mmol/L) 0.777 1.056 0.468
Hypertension(N/Y) 1.593 2.256 0.486
Table 11. Multiple linear regression analysis of CTRP1 and clinical indicators in single-vessel. *p < 0.05.
Variable β SE P
Sex(M/F) 12.408 13.942 0.381
Age(year) −0.723 0.829 0.390
Occlusion(N/Y) −3.458 13.430 0.799
Diabetes(N/Y) −32.302* 15.032 0.040
TCH(mmol/L) 0.190 5.196 0.971
HDL-C(mmol/L) −2.816 7.637 0.715
Smoker(N/Y) 2.251 17.093 0.896
AST(U/L) −0.092 0.128 0.478
TG(mmol/L) 0.145 3.202 0.964
Hypertension(N/Y) 25.093 14.429 0.093
Table 12. Multiple linear regression analysis of CTRP15 and clinical indicators in triple-vessel.
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